GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurogene Inc (NAS:NGNE) » Definitions » Inventories, Raw Materials & Components

NGNE (Neurogene) Inventories, Raw Materials & Components : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Neurogene Inventories, Raw Materials & Components?

Neurogene's inventories, raw materials & components for the quarter that ended in Dec. 2024 was $0.00 Mil.


Neurogene Inventories, Raw Materials & Components Historical Data

The historical data trend for Neurogene's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurogene Inventories, Raw Materials & Components Chart

Neurogene Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Inventories, Raw Materials & Components
- - - -

Neurogene Quarterly Data
Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Neurogene Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


Neurogene Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurogene Inc (NAS:NGNE) » Definitions » Inventories, Raw Materials & Components
Traded in Other Exchanges
Address
535 W 24th Street, 5th Floor, New York, NY, USA, 10011
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.